Rivaroxaban (Xarelto) plus Aspirin for Secondary Prevention of Cardiovascular Events

Date: December 3, 2018 Issue #:  1561Summary:  The FDA has approved a new 2.5-mg formulation of the direct factor Xa inhibitor rivaroxaban (Xarelto– Janssen) for use in combination with low-dose aspirin to reduce the risk of major cardiovascular events in patients with chronic coronary artery disease (CAD) or peripheral artery disease (PAD). Rivaroxaban is the first direct oral anticoagulant to be approved for this indication. It was approve d earlier for prevention and treatment of deep vein thrombosis (DVT) or pulmonary embolism (PE) and for prevention of stroke and systemic embolism in patients with nonvalvular atrial fibrillation.
Source: The Medical Letter - Category: Drugs & Pharmacology Authors: Source Type: research